CDS Welcomes Benevolent AI

How can we use artificial intelligence to discover new drugs?

These days, it’s impossible for any human being to process all the available data that we have collected — especially in the biotech and healthcare industries.

This is why we are increasingly turning to artificial intelligence companies like Benevolent AI to help us make sense of it all.

At the most recent Company Information Session, Benevolent AI explained how they’re applying artificial intelligence to a highly specific — and enormously vital — area of biotech and healthcare research: the discovery of new drugs.

Part of what they do involves using AI to aggregating previously untapped data sources.

Take research papers, for example. No scientist, as Benevolent AI’s CEO Jerome Pesenti pointed out, could ever read all the scientific papers in their field. So how can they ensure that they’re always updated on the newest developments?

Here is where Benevolent AI comes in. With the power to analyze almost 90 million research papers, not do they help scientists stay abreast of new developments, but they also have a pipeline in place for helping scientists generate hypotheses and experiments for new drug trails. This supports the larger goal of accelerating healthcare discoveries.

At present, they’re focused on expanding their platform to recruit more data scientists. (And, perhaps some of them will be CDS graduates!)

by Cherrie Kwok